NASDAQ
7.82USD
-0.32 (-3.93%)
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
484.7M
P/E
—
EPS
—
Beta
0.62
52W range
3.76-9.12
Day range
7.80–8.13
Open
8.13
Prev close
8.14
Volume
687.1K
Avg volume
1.2M
Dividend
0.00
IPO
2019-09-13
https://www.globenewswire.com/news-release/2026/08/03/3337414/0/en/Helus-Pharma-Appoints-Michael-Halstead-as-Chief-Executive-Officer.html · 8/3/2026+0.80
https://www.globenewswire.com/news-release/2026/07/21/3330358/0/en/Helus-Pharma-Completes-Enrollment-in-Phase-3-APPROACH-Study-of-HLP003-in-Adjunctive-Treatment-of-Major-Depressive-Disorder-Ahead-of-Schedule.html · 7/21/2026+0.80
https://seekingalpha.com/article/4921424-helus-pharma-stock-approaching-inflection-pivotal-readout-sets-up-asymmetric-upside · 7/12/2026+0.80
https://www.globenewswire.com/news-release/2026/06/29/3318875/0/en/Helus-Pharma-Reports-Recent-Business-Highlights-and-Fiscal-Year-2026-Financial-Results.html · 6/29/2026+1.00
https://seekingalpha.com/article/4874268-helus-pharma-cybin-stock-psychedelic-research-late-stage-clinical-neuroscience · 2/25/2026+0.40
Cybin Inc. functions as a biopharmaceutical company currently in its clinical development phase, concentrating on the advancement of novel therapeutic agents derived from psychedelic compounds. Its research pipeline includes CYB003, a deuterated psilocybin analog under investigation for major depressive disorder, and CYB004, a deuterated DMT compound being developed to address generalized anxiety disorder.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
